Suppliers / Inventaa Industries

Inventaa Industries

India Updated 9 July 2026

Inventaa Industries is an API manufacturer based in India. It holds one active US drug master file. Its most recent recorded inspection, by US FDA, closed on 28 June 2018 as NAI. Customs aggregates show $1.6M of exports covering 20 molecules to 8 destinations in 2025.

1
active US DMFs
0
valid CEPs
1
registered plants 1 with an FDA FEI number
0
filings across 0 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
1 of 1 confirmed
Inspections
2 of 2 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026.

Inspection history

  • 28 June 2018 NAI US FDA
  • 8 April 2016 VAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
India, India 3003903069

What they file, and where

Molecule Regulators Docs
Trimethoprim US FDA 1

Also appears on these molecule pages

Scale

Year Revenue Exports Destinations
2026 YTD Not reported $612K 3
2025 Not reported $1.6M 8
2024 Not reported $1.5M 9
2023 Not reported $2.7M 8

Export figures are customs aggregates. We do not publish the identity of any buyer.

Comparing suppliers?

Choose your molecules and target markets. Inventaa Industries comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Open risk flags

  • The most recent inspection outcome was NAI, on 28 June 2018.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability
Customs aggregates
Export values, molecule and destination counts